中國農產品交易(00149.HK)旗下玉林宏進進行股本重組 持股減至51%
中國農產品交易(00149.HK)公布,全資附屬龍群與中國股東就玉林宏進訂立股本重組協議。玉林宏進主要從事持有物業及經營玉林市場。
據協議,中國股東放棄其享有股息的權利,並指示將金額支付予龍群,及龍群於玉林宏進的註冊資本注資將減少金額相等於約4,190萬元人民幣。由於以上註冊資本注資的減少,龍群於玉林宏進的股權將減少至51%。
公司指,預期於玉林宏進,公司應佔權益總額將增加約2,500萬元。
中國股東為玉林宏進之主要股東。此外,中國農產品為宏安集團(01222.HK)及位元堂(00897.HK)的附屬公司,而位元堂為宏安的附屬公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.